retatrutide trial weight loss results Results: How Much Can You Lose & How Quick? Retatrutide phase 3 obesity trial
Description
Group, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial, Lancet, 373 (2009) 473481
Individual responses to compounds vary significantly
Ultimately, these actions are left up to shared decision-making
Baseline eGFR and UACR values in these studies suggest that participants were not predominantly at high-risk for CKD progression [80,81]
GLP-1 agonists are medications that mimic or boost the effects of this natural hormone
The challenge now is helping those who would benefit gain access
